287 related articles for article (PubMed ID: 30576361)
1. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.
Koskimäki F; Bernard J; Yong J; Arndt N; Carroll T; Lee SK; Reder AT; Javed A
PLoS One; 2018; 13(12):e0209326. PubMed ID: 30576361
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Intracortical Lesions on Volumes of Subcortical Structures in Multiple Sclerosis.
Kalinin I; Makshakov G; Evdoshenko E
AJNR Am J Neuroradiol; 2020 May; 41(5):804-808. PubMed ID: 32381540
[TBL] [Abstract][Full Text] [Related]
3. Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
Ciampi E; Pareto D; Sastre-Garriga J; Vidal-Jordana A; Tur C; Río J; Tintoré M; Auger C; Rovira A; Montalban X
Mult Scler; 2017 Apr; 23(4):556-566. PubMed ID: 27354019
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial.
Nakamura K; Sun Z; Hara-Cleaver C; Bodhinathan K; Avila RL
Mult Scler; 2024 May; 30(6):687-695. PubMed ID: 38469809
[TBL] [Abstract][Full Text] [Related]
5. Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
Sotirchos ES; Gonzalez-Caldito N; Dewey BE; Fitzgerald KC; Glaister J; Filippatou A; Ogbuokiri E; Feldman S; Kwakyi O; Risher H; Crainiceanu C; Pham DL; Van Zijl PC; Mowry EM; Reich DS; Prince JL; Calabresi PA; Saidha S
Mult Scler; 2020 Mar; 26(3):312-321. PubMed ID: 30741108
[TBL] [Abstract][Full Text] [Related]
6. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
Gaetano L; Häring DA; Radue EW; Mueller-Lenke N; Thakur A; Tomic D; Kappos L; Sprenger T
Neurology; 2018 Apr; 90(15):e1324-e1332. PubMed ID: 29540589
[TBL] [Abstract][Full Text] [Related]
7. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
[TBL] [Abstract][Full Text] [Related]
8. Cognitive impairment in early MS: contribution of white matter lesions, deep grey matter atrophy, and cortical atrophy.
Engl C; Tiemann L; Grahl S; Bussas M; Schmidt P; Pongratz V; Berthele A; Beer A; Gaser C; Kirschke JS; Zimmer C; Hemmer B; Mühlau M
J Neurol; 2020 Aug; 267(8):2307-2318. PubMed ID: 32328718
[TBL] [Abstract][Full Text] [Related]
9. Corpus callosum atrophy correlates with gray matter atrophy in patients with multiple sclerosis.
Klawiter EC; Ceccarelli A; Arora A; Jackson J; Bakshi S; Kim G; Miller J; Tauhid S; von Gizycki C; Bakshi R; Neema M
J Neuroimaging; 2015; 25(1):62-7. PubMed ID: 24816394
[TBL] [Abstract][Full Text] [Related]
10. Corpus callosum index correlates with brain volumetry and disability in multiple sclerosis patients.
Sugijono SE; Mulyadi R; Firdausia S; Prihartono J; Estiasari R
Neurosciences (Riyadh); 2020 Jul; 25(3):193-199. PubMed ID: 32683399
[TBL] [Abstract][Full Text] [Related]
11. A validation study of manual atrophy measures in patients with Multiple Sclerosis.
Cappelle S; Pareto D; Tintoré M; Vidal-Jordana A; Alyafeai R; Alberich M; Sastre-Garriga J; Auger C; Montalban X; Rovira À
Neuroradiology; 2020 Aug; 62(8):955-964. PubMed ID: 32246177
[TBL] [Abstract][Full Text] [Related]
12. Predictors of multiple sclerosis progression: A systematic review of conventional magnetic resonance imaging studies.
Lomer NB; Asalemi KA; Saberi A; Sarlak K
PLoS One; 2024; 19(4):e0300415. PubMed ID: 38626023
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic and Extrinsic Mechanisms of Thalamic Pathology in Multiple Sclerosis.
Mahajan KR; Nakamura K; Cohen JA; Trapp BD; Ontaneda D
Ann Neurol; 2020 Jul; 88(1):81-92. PubMed ID: 32286701
[TBL] [Abstract][Full Text] [Related]
14. Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.
Uher T; Vaneckova M; Krasensky J; Sobisek L; Tyblova M; Volna J; Seidl Z; Bergsland N; Dwyer MG; Zivadinov R; De Stefano N; Sormani MP; Havrdova EK; Horakova D
Mult Scler; 2019 Apr; 25(4):541-553. PubMed ID: 29143562
[TBL] [Abstract][Full Text] [Related]
15. Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study.
Galego O; Gouveia A; Batista S; Moura C; Machado E
Neuroradiol J; 2015 Jun; 28(3):354-8. PubMed ID: 26246109
[TBL] [Abstract][Full Text] [Related]
16. Age-dependent cut-offs for pathological deep gray matter and thalamic volume loss using Jacobian integration.
Opfer R; Krüger J; Spies L; Hamann M; Wicki CA; Kitzler HH; Gocke C; Silva D; Schippling S
Neuroimage Clin; 2020; 28():102478. PubMed ID: 33269702
[TBL] [Abstract][Full Text] [Related]
17. Differential Impact of Multiple Sclerosis on Cortical and Deep Gray Matter Structures in African Americans and Caucasian Americans.
Al-Kawaz M; Monohan E; Morris E; Perumal JS; Nealon N; Vartanian T; Gauthier SA
J Neuroimaging; 2017 May; 27(3):333-338. PubMed ID: 27634620
[TBL] [Abstract][Full Text] [Related]
18. Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines.
Chu R; Kim G; Tauhid S; Khalid F; Healy BC; Bakshi R
PLoS One; 2018; 13(11):e0206939. PubMed ID: 30408094
[TBL] [Abstract][Full Text] [Related]
19. Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates.
Rekik A; Aissi M; Rekik I; Mhiri M; Frih MA
Brain Behav; 2022 May; 12(5):e2573. PubMed ID: 35398999
[TBL] [Abstract][Full Text] [Related]
20. Characterization of gray-matter multiple sclerosis lesions using double inversion recovery, diffusion, contrast-enhanced, and volumetric MRI.
Parra Corral MA; Govindarajan ST; Stefancin P; Bangiyev L; Coyle PK; Duong TQ
Mult Scler Relat Disord; 2019 Jun; 31():74-81. PubMed ID: 30951968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
